Post by
dkeller85 on Jan 11, 2022 8:33am
Why this Canadian-Israeli Stock Grew 121% This Year
"Innocan Pharma operates three primary and distinct segments: research and development (R&D) of CBD-loaded exosomes, R&D of the use of CBD-loaded liposomes, and commercialization and sale of branded CBD-integrated pharmaceutical and topical treatment products."
tldr; INNO is bullish going into 2022, expect less volatility amidst ongoing gains as Innocan pushes towards its target price.
"https://www.entrepreneur.com/article/412265"